Phreesia Inc
NYSE:PHR
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
Phreesia Inc
NYSE:PHR
|
1.2B USD | -10.5 | ||
US |
Veeva Systems Inc
NYSE:VEEV
|
32.9B USD | 62.4 | ||
US |
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 19.6 | ||
US |
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 16.5 | ||
AU |
Pro Medicus Ltd
ASX:PME
|
12B AUD | 118.7 | ||
JP |
M3 Inc
TSE:2413
|
1.1T JPY | 12.4 | ||
US |
Inspire Medical Systems Inc
NYSE:INSP
|
5B USD | -137.9 | ||
US |
Doximity Inc
NYSE:DOCS
|
4.4B USD | 21 | ||
SE |
Sectra AB
STO:SECT B
|
44.4B SEK | -68.9 | ||
US |
Evolent Health Inc
NYSE:EVH
|
2.8B USD | 23.4 | ||
US |
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 264.4 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.